Keywords: Merck & Co, Novo Nordisk, Tresiba, Ryzodeg, Insomnia, Diabetes, USA, FDA, Advisory panel

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg

Article | 09 November 2012

Print This

US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's investigational insomnia ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in